Seres Therapeutics, Inc.: revenue
Revenue for Seres Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Seres Therapeutics, Inc. financial histories
What this measure means
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
Exact concept: us-gaap:Revenues. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 789,000 | USD | 2026-03-12 | 10-K · 0001193125-26-103276 |
| 2024-01-01 | 2024-12-31 | 0 | USD | 2026-03-12 | 10-K · 0001193125-26-103276 |
| 2023-01-01 | 2023-12-31 | 0 | USD | 2026-03-12 | 10-K · 0001193125-26-103276 |
| 2022-01-01 | 2022-12-31 | 7,128,000 | USD | 2024-03-05 | 10-K · 0000950170-24-025464 |
| 2021-01-01 | 2021-12-31 | 144,927,000 | USD | 2024-03-05 | 10-K · 0000950170-24-025464 |
| 2020-01-01 | 2020-12-31 | 33,215,000 | USD | 2023-03-07 | 10-K · 0000950170-23-006374 |
| 2019-01-01 | 2019-12-31 | 34,505,000 | USD | 2022-03-01 | 10-K · 0000950170-22-002435 |
| 2018-01-01 | 2018-12-31 | 28,267,000 | USD | 2021-03-02 | 10-K · 0001564590-21-010057 |
| 2017-01-01 | 2017-12-31 | 32,100,000 | USD | 2020-03-02 | 10-K · 0001564590-20-008002 |
| 2016-01-01 | 2016-12-31 | 21,766,000 | USD | 2019-03-06 | 10-K · 0001564590-19-006423 |
| 2015-01-01 | 2015-12-31 | 0 | USD | 2016-03-14 | 10-K · 0001564590-16-014692 |
Related financial histories
- Seres Therapeutics, Inc.: total assets
- Seres Therapeutics, Inc.: total liabilities
- Seres Therapeutics, Inc.: stockholders equity
- Seres Therapeutics, Inc.: cash and cash equivalents
- Seres Therapeutics, Inc.: net income or loss
- Seres Therapeutics, Inc.: operating cash flow
- Seres Therapeutics, Inc.: capital expenditure payments
- Seres Therapeutics, Inc.: contract revenue excluding tax
- Seres Therapeutics, Inc.: financing cash flow
- Seres Therapeutics, Inc.: investing cash flow
- Seres Therapeutics, Inc.: retained earnings or deficit
- Seres Therapeutics, Inc.: basic weighted-average shares
- Seres Therapeutics, Inc.: diluted weighted-average shares
- Seres Therapeutics, Inc.: basic earnings per share
- Seres Therapeutics, Inc.: diluted earnings per share
- Seres Therapeutics, Inc.: net property, plant and equipment
- Seres Therapeutics, Inc.: share-based compensation expense
- Seres Therapeutics, Inc.: operating income or loss
- Seres Therapeutics, Inc.: current assets
- Seres Therapeutics, Inc.: current liabilities
- Seres Therapeutics, Inc.: current accounts payable
- Seres Therapeutics, Inc.: net current accounts receivable
- Seres Therapeutics, Inc.: operating expenses
- Seres Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Seres Therapeutics, Inc. / CIK 0001609809
- Captured
- 2026-09-20T09:26:38.649Z
- SEC response SHA-256
105bfeb60dac37400daa54dfa3defd1c13ed7aa1d79341515907d114c9c517e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001609809.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))